CAR T-cell Therapy | Specialty

Dr. Maloney on the Registry for Real World Data of CAR T-Cell Therapy in ALL

September 13th 2019

David G. Maloney, MD, PhD, discusses the initiative to use the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry to report real world experience of tisagenlecleucel CAR T cells targeting CD19 in patients with acute lymphoblastic leukemia.

Dr. Sasine on New Developments With CAR T-Cell Therapy

September 13th 2019

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.

Emerging CAR T-Cell Therapies in Hematologic Cancers

September 6th 2019

Xiuli Wang, PhD, discusses emerging CAR T-cell therapy in hematologic cancers.

Dr. Sasine on Determining Outlook With CAR T-Cell Therapy in Hematologic Cancers

August 27th 2019

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Identifying Patients and Treating With CAR T-Cell Therapy

August 13th 2019

Stem Cell Transplantation and Novel Therapy

August 13th 2019

Optimizing Therapy for Patients With Multiple Myeloma

August 13th 2019

Navigating Through Testicular Cancer Treatment

August 13th 2019

Lisocabtagene Maraleucel Elicits Undetectable MRD in Relapsed/Refractory CLL

August 6th 2019

Tanya Siddiqi, MD, explains how novel agents are improving the treatment landscape for chronic lymphocytic leukemia, citing examples from the TRANSCEND CLL 004 trial.

Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin Lymphoma

August 5th 2019

Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.

Dr. Madduri on the Potential Impact of CAR T-Cell Therapy in Multiple Myeloma

August 3rd 2019

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the potential impact of CAR T-cell therapy in multiple myeloma.

Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCL

July 30th 2019

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

CAR T-Cell Therapy MB-102 Granted FDA Orphan Drug Designation for AML

July 25th 2019

The CAR T-Cell therapy MB-102 has been granted an Orphan Drug Designation by the FDA, according to Mustang Bio, Inc, the manufacturer of the investigational treatment.

Dr. Hou on the Latest Updates With CAR T-Cell Therapy in DLBCL

July 19th 2019

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Dr. Sehgal on Managing CRS and Neurotoxicity From CAR T-Cell Therapy

July 9th 2019

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses ways to manage cytokine release syndrome (CRS) and neurotoxicity associated with CAR T-cell therapy.

Best Practices With CAR T-Cell Therapy Being Refined in Lymphomas

July 3rd 2019

Alison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.

Expert Highlights CAR-T and Other Treatment Advances Across Hematologic Malignancies

July 2nd 2019

Mazyar Shadman, MD, MPH, discusses earlier use of CAR T-cell therapy in lymphoma, the impact of approved products on future development, and recent data with chemotherapy-free and time-limited therapy in chronic lymphocytic leukemia.

Dr. Shadman on Challenges With CAR T-Cell Therapy

June 28th 2019

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses challenges with CAR T-cell therapy.

Dr. Sehgal on the Structure and Manufacturing Process of CAR T Cells

June 28th 2019

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.

Dr. Galal on Managing AEs Linked With CAR T-Cell Therapy

June 25th 2019

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.